Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.64 |
| ▸ | PPARA | Q07869 | 20/20 | 0.64 |
| ▸ | PPARD | Q03181 | 6/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edaglitazone SCHEMBL29365673 | 1.00 | PPARG (0.64) | PPARGPPARAPPARD | |
| Edaglitazone SCHEMBL22607966 | 0.99 | PPARG (0.64) | PPARGPPARAPPARD | |
| SCHEMBL5974182 | 0.94 | PPARG (0.64) | PPARGPPARAPPARD | |
| SCHEMBL6020885 | 0.94 | PPARG (0.63) | PPARGPPARAPPARD | |
| SCHEMBL12974506 | 0.94 | PPARG (0.63) | PPARGPPARAPPARD | |
| SCHEMBL5743266 | 0.93 | PPARG (0.62) | PPARGPPARAPPARD | |
| SCHEMBL3745188 | 0.93 | PPARG (0.55) | PPARGPPARAPPARD | |
| SCHEMBL3743468 | 0.93 | PPARG (0.55) | PPARGPPARAPPARD | |
| SCHEMBL3730093 | 0.92 | PPARG (0.56) | PPARGPPARAPPARD | |
| SCHEMBL7619881 | 0.91 | PPARG (0.54) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323481-B2 | Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth | HOFFMANN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | claimed |
| EP-1641790-A1 | PROCESS FOR THE PREPARATION OF INSULIN SENSITIZER AND INTERMEDIATE COMPOUND THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-05 | — | — | EP | claimed |
| EP-1078923-B1 | Process for the preparation of benzothiophene derivatives | HOFFMANN LA ROCHE (CH) | 2006-03-08 | — | — | EP | claimed |
| US-20050176787-A1 | Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-11 | — | — | US | claimed |
| EP-1282619-B1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | EP | claimed |
| WO-2005000844-A1 | PROCESS FOR THE PREPARATION OF INSULIN SENSITIZER AND INTERMEDIATE COMPOUND THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | claimed |
| EP-1392296-A1 | THIAZOLIDINEDIONES ALONE OR IN CONBINATION WITH OTHER THERAPEUTIC AGENTS FOR INHIBITING OR REDUCING TUMOUR GROWTH | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-03 | — | — | EP | claimed |
| US-20040024222-A1 | Process for the preparation of thiazolidinedione derivatives | SCALONE MICHELANGELO (CH) | 2004-02-05 | — | — | US | claimed |
| US-20030092916-A1 | Process for the preparation of thiazolidinedione derivatives | SCALONE MICHELANGELO (CH) | 2003-05-15 | — | — | US | claimed |
| EP-1282619-A1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | claimed |
| WO-2002080913-A1 | THIAZOLIDINEDIONES ALONE OR IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR INHIBITING OR REDUCING TUMOUR GROWTH | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-17 | — | — | WO | claimed |
| EP-0700397-B1 | NEW THIAZOLIDINDIONES AND DRUGS CONTAINING THEM | ROCHE DIAGNOSTICS GMBH (DE) | 2002-09-04 | — | — | EP | claimed |
| US-6437144-B2 | CYCLOCARBONYLATION | HOFFMANN-LA ROCHE INC. | 2002-08-20 | — | — | US | claimed |
| US-20010049445-A1 | Process for the preparation of thiazolidinedione derivatives | HOFFMANN-LA ROCHE INC. | 2001-12-06 | — | — | US | claimed |
| WO-2001079202-A1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-25 | — | — | WO | claimed |
| US-6258832-B1 | REDUCTION OF COMPOUNDS WITH ALUMINUM IN APROTIC SOLVENT | ROCHE DIAGNOSTICS GMBH (DE) | 2001-07-10 | — | — | US | claimed |
| EP-1078923-A2 | Process for the preparation of benzothiophene derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-28 | — | — | EP | claimed |
| US-5599826-A | ANTIDIABETIC AGENT | BOEHRINGER MANNHEIM GMBH (DE) | 1997-02-04 | — | — | US | claimed |
| US-11746354-B2 | Homology dependent repair genome editing | INARI AGRICULTURE TECHNOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-1994027995-A1 | NEW THIAZOLIDINDIONES AND DRUGS CONTAINING THEM | BOEHRINGER MANNHEIM GMBH (DE) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176787-A1 | Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth | PPARD, PPARG, PPARA | PPARG 2/4885PPARA 3/4885PPARD 1/4885 |
| US-20030092916-A1 | Process for the preparation of thiazolidinedione derivatives | SLC5A2, CYP4B1, CYP4F3 | PPARG 80/4885PPARA 182/4885PPARD 45/4885 |
| US-20010049445-A1 | Process for the preparation of thiazolidinedione derivatives | SLC5A2, CYP4B1, CYP4F3 | PPARG 80/4885PPARA 182/4885PPARD 45/4885 |
| US-20040024222-A1 | Process for the preparation of thiazolidinedione derivatives | SLC5A2, CYP4B1, CYP4F3 | PPARG 80/4885PPARA 182/4885PPARD 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.